Abbott Gains Go-Ahead For First 'No-Fingerstick' CGM
Executive Summary
Abbott Laboratories' Freestyle Libre Flash is the first continuous glucose monitoring system to gain US FDA approval that lets diabetics avoid the additional step of fingerstick calibration to measure their glucose levels, "with the wave of a mobile reader," the agency says.
You may also be interested in...
Bigfoot Biomedical Raised $55m, Including Backing From Abbott
Bigfoot Biomedical said it raised $55m in a Series B financing, including a new undisclosed investment from partner Abbott Laboratories, bringing the start-up's total funding to $90m. The diabetes firm said it plans to use the money to fund clinical trials and marketing of its insulin pump and pen.
Dexcom Gains Approval For No-Calibration, 'Interoperable' CGM System
US FDA's March 27 de novo clearance of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for diabetics gives Dexcom a no-calibration offering, a first-in-class "interoperable" system and sets out a streamlined regulatory pathway for future CGM devices with similar features.
Abbott 'No-Fingerstick' CGM System For Diabetes Wins Medicare Coverage
The first continuous glucose monitoring (CGM) system for diabetics that avoids fingerstick calibrations, the Abbott Freestyle Libre, now will be covered through Medicare under therapeutic CGM systems reimbursement codes.